About Transitional endoplasmic reticulum ATPase
Transitional endoplasmic reticulum ATPase (VCP) is a protein
from Homo sapiens identified by UniProt accession
P55072, 806 residues long.
MolForge cross-references it against 0 known binders and
510 disease associations.
Target properties
| Protein name | Transitional endoplasmic reticulum ATPase |
|---|
| UniProt accession | P55072 |
|---|
| Gene | VCP |
|---|
| Organism | Homo sapiens |
|---|
| Length | 806 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (4)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (510)
Diseases linked to this target (Open Targets).
- inclusion body myopathy with Paget disease of bone and frontotemporal dementia type 1 · score 0.80
- frontotemporal dementia and/or amyotrophic lateral sclerosis 6 · score 0.75
- amyotrophic lateral sclerosis · score 0.72
- inclusion body myopathy with Paget disease of bone and frontotemporal dementia · score 0.70
- Charcot-Marie-Tooth disease type 2Y · score 0.69
- familial amyotrophic lateral sclerosis · score 0.57
- neurodegenerative disease · score 0.51
- cystic fibrosis · score 0.46
- holoprosencephaly · score 0.46
- frontotemporal dementia with motor neuron disease · score 0.45
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P55072-F1 | alphafold | PREDICTED | 82.59 | — |
Amino-acid sequence (806 residues)
MASGADSKGD DLSTAILKQK NRPNRLIVDE AINEDNSVVS LSQPKMDELQ LFRGDTVLLK GKKRREAVCI VLSDDTCSDE KIRMNRVVRN NLRVRLGDVI SIQPCPDVKY GKRIHVLPID DTVEGITGNL FEVYLKPYFL EAYRPIRKGD IFLVRGGMRA VEFKVVETDP SPYCIVAPDT VIHCEGEPIK REDEEESLNE VGYDDIGGCR KQLAQIKEMV ELPLRHPALF KAIGVKPPRG ILLYGPPGTG KTLIARAVAN ETGAFFFLIN GPEIMSKLAG ESESNLRKAF EEAEKNAPAI IFIDELDAIA PKREKTHGEV ERRIVSQLLT LMDGLKQRAH VIVMAATNRP NSIDPALRRF GRFDREVDIG IPDATGRLEI LQIHTKNMKL ADDVDLEQVA NETHGHVGAD LAALCSEAAL QAIRKKMDLI DLEDETIDAE VMNSLAVTMD DFRWALSQSN PSALRETVVE VPQVTWEDIG GLEDVKRELQ ELVQYPVEHP DKFLKFGMTP SKGVLFYGPP GCGKTLLAKA IANECQANFI SIKGPELLTM WFGESEANVR EIFDKARQAA PCVLFFDELD SIAKARGGNI GDGGGAADRV INQILTEMDG MSTKKNVFII GATNRPDIID PAILRPGRLD QLIYIPLPDE KSRVAILKAN LRKSPVAKDV DLEFLAKMTN GFSGADLTEI CQRACKLAIR ESIESEIRRE RERQTNPSAM EVEEDDPVPE IRRDHFEEAM RFARRSVSDN DIRKYEMFAQ TLQQSRGFGS FRFPSGNQGG AGPSQGSGGG TGGSVYTEDN DDDLYG
Explore Transitional endoplasmic reticulum ATPase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets